Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

Shanghai Jiao Tong University

Status: Completed

Conditions: Liver Transplantation

Treatments: Combination Product: PVHA or TACE

Study type: Observational

Funder types: Other

Identifiers

NCT05448339

SHLTQC-5

Details and patient eligibility

About

To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.

Enrollment: 197 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

(1) age ≥18 years; (2) exceeding UCSF criteria; (3) absence of vascular invasion, nodal involvement, or extrahepatic metastases; (4) receiving TACE treatment or LTFVD treatment for downstaging purposes.

Trial design

197 participants in 2 patient groups

PVHA

Description:

Patients undergo tumor feeding vessels deprivation

Treatment:

Combination Product: PVHA or TACE

TACE

Description:

Patients undergo TACE therapy

Treatment:

Combination Product: PVHA or TACE